Please fill out the form below and we will gladly respond as soon as possible.
Zelluna ASA, a Norwegian biotech company pioneering allogeneic cell therapies for solid cancers, recently announced that the first patient has received the first dose of ZI-MA4-1 in the ZIMA-101 Phase 1 clinical trial. The treatment was administered at The Christie NHS Foundation Trust in Manchester, United Kingdom, the largest single-site cancer centre in Europe, marking […]
A case report in AME Case Reports by Yun Xiao, Zhourui Liu, and Sha Li of the Department of Ultrasound at Guizhou Medical University, China, documents a rare case of synovial sarcoma arising directly in the pulmonary artery, a location so uncommon that it was initially mistaken for a benign cardiac tumor. What the Case […]
A new educational review in the American Society of Clinical Oncology Educational Book, authored by Sophie Jessop, MBBS, and colleagues, examines three persistent gaps in care for adolescents and young adults (AYAs) with sarcoma: clinical trial access, genetic testing for inherited cancer risk, and timely palliative care. The piece is grounded by the firsthand perspective […]
A new profile by Mariella Bodemeier Loayza Careaga, PhD, published in The Scientist, revisits biochemist Cigall Kadoch’s research nearly a decade after the publication first covered her work, tracing how her lab has continued to map the molecular hijacking that drives synovial sarcoma. The BAF Complex and the SS18-SSX Fusion Kadoch’s research centers on BAF […]
The Synovial Sarcoma Foundation is excited to announce that we have funded a new Data Staff Scientist position at Children’s Hospital of Philadelphia (CHOP), Philadelphia Campus, a major step forward in our mission to accelerate research and improve outcomes for patients with synovial sarcoma. What This Role Will Do The person selected for this role […]
US WorldMeds® announced that the U.S. Food and Drug Administration has granted full approval to TECELRA® (afamitresgene autoleucel), with an expanded indication that now includes eligible patients as young as 12 years old. The therapy, which received its original accelerated approval in August 2024, remains the first and only FDA-approved engineered T-cell therapy for a […]
11 Leading Oncologists and Researchers Unite to Accelerate Progress for Synovial Sarcoma Patients PHILADELPHIA [June 22, 2026] The Synovial Sarcoma Foundation (SSF) today announced the formation of its Medical Advisory Board, bringing together 11 internationally recognized clinicians and researchers to serve as the central coordinating body for synovial sarcoma research, treatment, and advocacy. The board […]
A landmark study from Jerby-Arnon, Neftel, Shore, and colleagues at the Broad Institute of Harvard and MIT, Massachusetts General Hospital, Dana-Farber Cancer Institute, and the University of Lausanne used single-cell RNA sequencing to profile 16,872 individual cells from 12 human synovial sarcoma tumors – one of the most detailed cellular portraits of this disease ever […]
A case report published in Frontiers in Oncology by Miyazaki, Oike, and colleagues at Niigata University Graduate School of Medical and Dental Sciences, Japan, documents a rare synovial sarcoma presentation that defeated every standard diagnostic test – and delayed correct treatment by over three years. The case carries urgent lessons for patients, advocates, and clinicians […]
A new case report published in the World Journal of Surgical Oncology explored an innovative reconstruction technique for rare soft tissue sarcomas of the hand and foot, including synovial sarcoma. The study was authored by Naoya Terao, Naoki Oike, Takashi Ariizumi, and colleagues, with research conducted primarily through the Division of Orthopedic Surgery at Niigata […]
